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The vast majority of patients hospitalized with acute heart failure (AHF) initially present 
to the emergency department (ED).  Correct diagnosis followed by prompt treatment 
ensures optimal outcomes.  We recommend a 6-axis model to ensure comprehensive 
initial care of the AHF patient.   
 
Key Points (3–5) 
• Use of lung ultrasound significantly improves diagnostic accuracy 
• Robust evidence to treat AHF in the ED setting remains poor.  However, existing 
therapies improve symptoms and hemodynamics 
• Use a framework to ensure optimal management of the AHF patient. We 
recommend the 6-axis model 
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Introduction 
Few other acute presentations result in such paradoxical outcomes as acute 
heart failure (AHF). Patients feel substantially better with current treatment, yet 
outcomes are dismal – up to 1/3rd of hospitalized patients experience death or re-
hospitalization within the next 3 months1 – suggesting initial improvements fail to 
address the underlying problem.  Akin to treating the fever yet ignoring the abscess. 
Despite substantial efforts, outcomes have improved little in absolute terms over the last 
10 years. With over one million hospitalizations annually in the United States,2 
improving outcomes remains the greatest unmet need in AHF management. 
 
Background 
The emergency department (ED) is the beginning of hospital based management 
for over 80% of AHF patients in the United States.3-5  Patients most commonly present 
with shortness of breath or dyspnea.6-8  Given the broad differential for such a chief 
complaint, correct diagnosis is paramount yet can be challenging, especially for patients 
with multiple co-morbidities.  Since there is no gold standard – heart failure remains a 
clinical diagnosis – diagnostic accuracy in the ED ranges from 71 to 86%.9  At times, the 
patient’s condition mandates treatment before a definitive diagnosis is made.  
Unfortunately, the evidence base for the pharmacologic management of AHF in the ED 
is poor, with no guideline recommendations meeting the highest Level 1, Class A 
grade.10-12  While modern day management has evolved away from rotating tourniquets 
and blood-letting, the remaining pharmacologic armamentarium for AHF management is 
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largely the same as 50 years ago.13  Lack of evidence does not mean current therapies 
are ineffective, however. 
 
Diagnosis 
As mentioned, patients presenting in extremis requiring simultaneous treatment 
as the diagnosis is confirmed. However, for most patients, sufficient time exists to form 
an initial diagnostic and treatment plan. 
AHF is a clinical diagnosis. Thus, no single blood test, image, historical feature or 
exam finding absolutely confirms the presence of HF.  In fact, the sensitivity of classic 
HF exam findings is quite poor. An S3 and jugular venous distention are quite specific, 
however their sensitivity and inter-rater reliability is poor.14 With the advent of natriuretic 
peptides, diagnostic accuracy has improved considerably.15 However, a recent 
systematic review examining the clinical utility of natriuretic peptides using interval 
likelihood ratios – to better account for NP as a continuous variable – suggests the 
diagnostic ‘power’ of NP lies more in ruling out AHF.  To ‘rule-in’ AHF, lung ultrasound 
(LUS) is one of the most useful, easy, and rapid tests to perform at the bedside.9,16 
[FIGURE of US B-LINES]  Although multiple scoring systems exist to quantify the 
number of B-lines, the presence of multiple B-lines in at least 2 areas of each hemi-
thorax aids in the diagnosis of AHF in the appropriate clinical setting.  
 
Initial Classification 
 Perhaps more than any other term, heterogeneity best describes the AHF 
population.  In addition to differences in cardiac structure and function, underlying 
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etiology of HF, and precipitant of AHF, marked differences in patient characteristics, co-
morbid conditions, and background therapies, highlights the challenges of a singular, 
uniform construct to manage all AHF. As discussed in more detail below, we 
recommend the importance of thorough knowledge of underlying cardiac substrate, 
precipitants, and amplifying mechanisms of decompensation to best manage manage, 
accounting for patient differences. Nevertheless, some baseline characteristics are 
worth highlighting.  Patients are older, with an average age of 73 years, with women 
comprising approximately half of AHF presentations.17  Of note, nearly half of AHF 
patients have a relatively preserved (>40%) ejection fraction.  Like AHF, no 
pharmacologic therapy definitively improves outcomes for patients with HF and a 
preserved ejection fraction (HFpEF).10,12 This is a fundamental difference compared to 
HF with reduced EF (HFrEF).  However, mineralocorticoid receptor antagonists are a 
potential notable exception.18 Irrespective of a reduced vs. preserved EF, the co-morbid 
burden for AHF is high, particularly for ischemic heart disease, diabetes, atrial 
fibrillation, and hypertension as well as COPD. 
 Given the heterogeneity of the patient population and presentation, we propose a 
construct to aid the acute care provider in initial management.   This is taken from the 
Braunwald and Gheorghiade 6-axis model.19  Before in-depth discussion of the model, it 
is important to highlight what we consider less important in the ED setting. 
 
Preserved vs. Reduced EF 
No specific mention of HFpEF vs. HFrEF is mentioned.  Although these are the most 
commonly used terms currently, past terms such as diastolic dysfunction and systolic 
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dysfunction have also been used to broadly describe patients based on EF.  For the 
acute care physician, with a few exceptions noted below, acute management does not 
significantly differ based on EF.  Blood pressure, for example, better captures this 
difference in EF; few HFpEF patients will present with marked low SBP due to poor 
pump function.  Where knowledge of EF matters most, is in chronic management.   
 Although knowledge of EF does not commonly change acute management, 
bedside or formal ECHO may aid in diagnosing the extent and severity of right sided 
failure, presence of pericardial fusion, and valvular disease.  Such knowledge may also 
aid in immediate management. 
 
6-axis Approach to AHF Management 
The 6-axis model is a guide to management, establishing a multi-faceted framework to 
ensure the clinician considers various key aspects of initial AHF management.  Certain 
aspects may be of greater importance depending on the patient. Importantly, the 6-axis 
model is intended to be dynamic: re-evaluation is essential.  At each point of evaluation 
and re-evaluation, except for de novo vs. chronic HF, each axis should be considered.  
For example, initial presentation may differ from pre-discharge in regards to the 
importance of each axis.  (See Figure 2) Response to management or failure to 
respond, as well as results of testing may yield new insights to further tailor 
management.   
 
Clinical Severity 
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Initial clinical impression guides urgency of management.  Vital signs are an essential 
and rapid gauge of severity. Patients who present in extremis require immediate 
stabilization and resuscitation.  Examples include flash pulmonary edema and 
cardiogenic shock.  For both, symptomatic management is important but secondary to 
identification and treatment of the underlying precipitant. 
 
Blood Pressure 
Systolic blood pressure is a known prognostic marker in AHF; higher SBP patients have 
better outcomes.1  We recommend further sub-classification based on SBP to guide 
initial therapeutic choices.20  Although there is considerable overlap, we use cut-points 
to aid the clinician: (hypotensive = < 100mmHg, normotensive as 100-140, and 
hypertensive as > 140mmHg).  Most AHF patients present ‘warm and wet.’21  Although 
the SBP is an excellent guide, it is based on this assumption of ‘warm and wet.’  
Patients who are ‘cold and wet’ – have systemic vasoconstriction but a low cardiac 
output – may have poor end organ perfusion despite a relatively normal SBP. 
Table 1 Hypotensive Normotensive Hypertensive 
IV loop 
diuretics 
 ++++ ++ 
Vasodilators  ++ ++++ 
Inotropes ++++   
For the hypotensive patient, assessment of volume status is challenging.  Patients with 
a history of severely reduced ejection fraction may have a low SBP at baseline.  Thus, 
reflexive diagnosis of shock is discouraged.  Though rarely done by the emergency 
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physician, decongestive strategies (i.e. vasodilators and IV loop diuretics) may be used 
to optimize loading conditions for such patients. These patients are amongst the most 
challenging to manage acutely. 
 
Heart Rate and Rhythm 
For patients with severe systolic dysfunction, HR is the major contributor to 
cardiac output, given the minimal ability to augment stroke volume.  Thus, bradycardias, 
even if minor, may impair cardiac output.  On the other hand, in the setting of a stiff left 
ventricle (or diastolic dysfunction) a very rapid heart rate may be deleterious. For these 
patients, reduced filling time in the setting of decrease left ventricle compliance may 
initiate or propagate AHF symptoms.  
The most common dysrhythmia to present in the context of AHF is atrial 
fibrillation (AF).  A history of AF is a risk factor for developing HF and vice-versa.  For 
some patients, their first presentation of AHF may be due to AF with rapid ventricular 
response.  For unstable patients, follow guideline recommended protocols; specifically 
cardioversion.  For most patients however, treatment of AF follows a well-established 
paradigm of asking the following questions:  1) Rhythm control?  2) Rate control?  3) 
Risk stratify for stroke.  
 For patients with a known history of AF, management of AHF itself may lower the 
heart rate by reducing adrenergic drive.  In patients with a preserved EF, HR control is 
particularly important, given the ‘stiffness’ or lack of compliance of the left ventricle.  By 
definition, a faster HR results in relatively less filling time.  With decreased LV 
compliance, a faster HR may result in worsening signs and symptoms of AHF.   
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 Common rate control agents, such as non-dihydropyridines and beta blockers 
are commonly used to treat AF in the setting of AHF. Although less commonly used, 
digoxin should also be considered.22  For patients with a preserved EF, rate control will 
improve loading conditions and symptoms.  For patients with reduced EF, caution is 
warranted before reflex use of non-dihydropyridines or beta blockers.  Permissive 
tachycardia may be needed to ensure sufficient cardiac output, given these patients 
may be unable to augment stroke volume.   
 
Precipitants 
Identification and treatment of the precipitant of AHF is fundamental to good AHF 
management.  Contrary to tradition, medication non-compliance and dietary indiscretion 
are not the most common causes of decompensation.23  Rather, infection and ischemia 
are more common.   Failure to identify the underlying cause is not just an ED 
phenomenon; a remarkable proportion of patients with new onset heart failure never 
have an evaluation for underlying ischemic heart disease either during hospitalization or 
in the following months after presentation.24 
 
Co-morbidities 
Among the many challenges of managing AHF, consideration of the patients’ CV 
and non-CV conditions is necessary to ensure overall excellent care.  At the time of 
presentation, a COPD exacerbation or uncontrolled diabetes may trigger 
decompensation. In general, management of both HF and other co-morbidities will 
occur once the patient is stabilized. 
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De novo vs. decompensated Chronic HF. 
As a general rule, we suggest admission for patients with de novo or new onset 
HF.  In addition to further management, understanding underlying cardiac structure and 
function, presence or absence of coronary artery disease, as well as education 
regarding a new chronic disease may be challenging to perform expeditiously in the 
outpatient setting. A three-prong pathophysiologic approach may be considered: 1) 
Cardiac substrate 2) Triggers or precipitants 3) Amplifying mechanisms.25  After 
stabilization, each should be considered and managed appropriately. For all patients, 
adherence to guideline recommended therapies are essential.  For chronic HF patients, 
thorough evaluation has ideally, already occurred; hospitalization presents an 
opportunity for further education and optimization of guideline directed medical therapy. 
 
Risk-stratification and Disposition 
Although over 80% of AHF patients are admitted from the ER, not all require 
hospitalization.3,26,27  Over a decade ago, one report suggested nearly 50% of AHF 
patients could be discharged home.28  Unfortunately, for the small proportion of patients 
discharged, little is known regarding their outcomes.  The best evidence comes from 
Canadian datasets, suggesting emergency physicians risk stratify poorly, with 
discharged patients at higher risk for bad outcomes.29  Existing risk instruments either 
fail to perform well enough or have yet to be well-validated.  Thus, evidence based, 
universal recommendations regarding who is safe to discharge do not yet exist.   
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Lack of evidence has not hindered efforts to decrease hospital re-admissions 
however.30  Similarly, expert consensus, informed by existing evidence, should inform 
individual hospital or health care system strategies to reduce hospital admissions from 
the ED. 
Overall, emergency physicians have a low tolerance for risk.31  Suggesting ED’s 
move from over 80% admission to 50 or 60% would be difficult, especially absent better 
evidence.  Observation units or short-stay units are a viable alternative to direct 
discharge. 
 
Observation Units for Heart Failure 
Observation for AHF patients has been ongoing for well over a decade.32,33  Both 
retrospective analyses and small studies support the safety, effectiveness and potential 
cost-savings of AHF observation unit (OU) management.5,34-40 In a retrospective study 
of 358 patients using Society of Cardiovascular Patient Care guidelines, the authors 
observed less hospital bed day utilization and similar 30-day readmission rates (12.5% 
vs 10.0%), respectively after adjustment for age, race, sex, BNP, renal function and 
ejection fraction.39 Patients who weren’t ready for discharge after SSU management 
were admitted to the hospital for further treatment. 
Compared to low-risk chest pain patients sent to the OU for ‘rule-out’ ACS, AHF 
patients are older with significantly more co-morbidities.  While follow up after 
observation is important for all patients, ensuring a seamless handoff after an AHF 
exacerbation is especially so.  Thus, an excellent working relationship with cardiologists 
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is critical to ensure a successful OU strategy. Figure 3 below is a suggested algorithm 
for ED disposition. 
 
 
 
 Observation also affords a luxury generally absent in the ED setting: time. Thus, 
response to therapy, assessment of functional status, addressing co-morbidities, as well 
as education, follow up, contact with the primary cardiologist or primary care physicians 
can occur.  Furthermore, time for social work and case management consultation is also 
possible.  As mentioned earlier, the 6-axis model should be considered during each 
phase of re-evaluation to optimize care.   
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Other Considerations 
 Observation (or hospitalization) is an opportunity to optimize (or plan to optimize) 
care.  Figure 4 outlines different facets of AHF to consider prior to discharge. Not all 
have to be performed during hospitalization; however, each should be considered.  
 
Future Directions 
While outcomes from AHF have improved slightly over the last decade, overall, 
prognosis remains poor. Over a third of patients will die or be re-hospitalized within 90 
days after discharge.1 Attempts to improve outcomes with novel therapies have largely 
failed. Such failures suggest improving mortality with a short-term infusion during 
hospitalization is a daunting hurdle.41 While the reasons for such lack of success is 
beyond the scope of this article, our limited knowledge of the underlying 
pathophysiology of AHF – in all its forms – has likely contributed.  To this day, an exact 
agreement on the definition of AHF remains debated. 
Lack of success does not mitigate the pressing and growing unmet need.  The 
ED continues to play a critical role in initial diagnosis and management and arguably 
‘sets the tone’ for downstream management.  Ideally, the correct path is followed. 
However, poor upfront management also has potential deleterious downstream 
consequences. Importantly, the decision to admit or not – one of the costliest healthcare 
decisions financially – remains an area of ongoing work.  Improvements in risk-
stratification will decrease the number of hospitalizations for many patients. 
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Although we recommend the 6-axis model as a framework for initial 
management, testing and validation of the model is still required. In the future additional 
components might be added (SEE FIGURE 5) or removed.  In this example of an 8-axis 
model, both CAD and biomarker profiles have been added. At the present, robust 
assessment of CAD during hospitalization is not routine, nor should it be for every 
patient.  However, ischemia due to CAD may be a direct contributor to decompensation.  
Whether intervention results in better outcomes is speculative.42,43 Existing and yet-to-
be-discovered biomarkers may also influence management and treatment. One 
example are high-sensitivity troponin assays.  Although a large proportion of AHF 
patients present with evidence of high-sensitivity troponin release, the exact reasons 
and how to manage such patients remain areas of active investigation. One potential 
role of biomarkers would be risk-stratification.44 
Given the multimorbid burden of AHF patients, decreasing disparities remains a 
critical area to improve outcomes.  Such patients bear a disproportionate burden of 
health care utilization and worse outcomes.3,45 Novel ideas such as community 
paramedicine may have a role.46,47  From the ED perspective, moving from a 
transactional health encounter to one that is a part of the longitudinal care of patients 
will be essential.   
 
Summary/Discussion 
Most patients hospitalized with AHF initially present to the ED.  Ensuring correct 
diagnosis and prompt management is critical to ensure good outcomes. We recommend 
the 6-axis model as a framework for initial management of the ED AHF patient. 
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Importantly, re-assessment should occur frequently.  Rather than hospitalize most 
patients, use of observation units may provide the necessary and sufficient time to 
ensure patients are responding appropriately to initial management. Time in observation 
also allows for more robust transitional care, ensuring good communication with primary 
care and specialists as well as addressing other co-morbid conditions, education, and 
social factors.. 
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Fig. 1
Lung ultrasound. Arrows point to B-lines.
Fig. 2
The 6-axis model. ( A ) Represents initial ED presentation and management. ( B ) Highlights how certain 
components of the 6-axis model may increase or decrease in importance during hospitalization. ( C ) 
Further highlights the dynamic nature of AHF. By discharge, ensuring comorbidities were addressed is 
critical. Whether or not the patient had de novo vs chronic HF might significantly impact further disease 
management.
( From Gheorghiade M, Braunwald E. A proposed model for initial assessment and management of acute 
heart failure syndromes. JAMA 2011;305(16):1703; with permission.)
Fig. 3
ED disposition of patients with AHF.
( From Miro O, Levy PD, Mockel M, et al. Disposition of emergency department patients diagnosed with acute heart 
failure: an international emergency medicine perspective. Eur J Emerg Med 2017;24(1):2–12; with permission.)
Fig. 4
Comprehensive assessment and targeted implementation of evidence-based therapies. ACE-I, angiotensin 
converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT, chronic resynchronization therapy; 
Hydral, hydralazine; ICD, implantable cardiac defibrillator; ISDN, isosorbide dinitrate; JVP, jugular venous 
pulse; LV, left ventricle. a Select patients. b Viable but dysfunctional myocardium.
( Adapted from Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart 
failure syndromes. Eur Heart J 2010;31(7):784–93; with permission.)
Fig. 5
Potential to Expand the 6-axis Model.
( Data from Gheorghiade M, Braunwald E. A proposed model for initial assessment and management of acute 
heart failure syndromes. JAMA: the journal of the American Medical Association 2011;305(16):1702–3.)

